CASIFOTCPharmaceutical PreparationsFiscal year ends December 31
CASI Pharmaceuticals, Inc.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 15, 2026
$0.10+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
CASI Pharmaceuticals statistics
Financials through Dec 31, 2025, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | CASI Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $2.06M | $166.30M |
| Enterprise Value | $15.62M | $88.19M |
| PS Ratio | 0.10 | 3.65 |
Enterprise value
| Measure | CASI Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 0.75 | 2.51 |
Income (trailing twelve months)
| Measure | CASI Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $20.71M | $58.34M |
| Gross Profit | $10.08M | $105.94M |
| Operating Income | -$45.01M | -$21.40M |
| Pretax Income | -$45.87M | -$14.34M |
| Net Income | -$48.06M | -$22.46M |
| EBITDA | -$43.81M | -$16.91M |
| EPS (Diluted) | -$2.59 | -$0.83 |
Margins
| Measure | CASI Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 48.6% | 52.9% |
| Operating Margin | -217.3% | -44.0% |
| Pretax Margin | -221.5% | -13.3% |
| Profit Margin | -232.0% | -40.2% |
| EBITDA Margin | -211.5% | -30.2% |
| FCF Margin | -100.3% | -9.27% |
Returns
| Measure | CASI Pharmaceuticals | Industry median |
|---|---|---|
| Return on Assets (ROA) | -121.2% | -40.9% |
Growth
| Measure | CASI Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -27.4% | 5.96% |
| Revenue Growth (3Y CAGR) | -21.7% | 2.25% |
| Revenue Growth (5Y CAGR) | 6.47% | 6.48% |
Balance sheet
| Measure | CASI Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $5.63M | $61.43M |
| Total Debt | $19.19M | $118.52M |
| Net Cash (Debt) | -$13.56M | $15.35M |
| Net Cash Per Share | -$0.66 | $0.66 |
| Equity (Book Value) | -$37.28M | $49.09M |
| Book Value Per Share | -$1.81 | $1.37 |
| Tangible Book Value | -$37.50M | $23.52M |
| Working Capital | -$36.21M | $76.81M |
Financial position
| Measure | CASI Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 0.27 | 3.34 |
| Quick Ratio | 0.20 | 2.44 |
Cash flow (trailing twelve months)
| Measure | CASI Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$20.75M | -$12.35M |
| Capital Expenditures | -$16.00K | -$1.08M |
| Free Cash Flow | -$20.77M | -$20.22M |
| FCF Per Share | -$1.01 | -$0.42 |
Efficiency
| Measure | CASI Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.52 | 0.39 |
| Inventory Turnover | 3.11 | 2.70 |
| Revenue Per Employee | $96.79K | $404.87K |
| Profits Per Employee | -$224.57K | -$703.34K |
| Employee Count | 214 | 74 |
Dividends and yields
| Measure | CASI Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -2335.6% | -23.3% |
| FCF Yield | -1009.4% | -8.72% |
Shares
| Measure | CASI Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 20,555,900 | 58,127,000 |
| Shares Change (YoY) | 20.8% | 10.9% |
Scores
| Measure | CASI Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -47.49 | -0.22 |
| Piotroski F-Score | 4 | 4 |
| Beneish M-Score | -8.79 | -2.62 |
Calculated by StockData from CASI Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.